Literature DB >> 18823257

Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD.

Martina Schulte1, Karim Osseiran, Reiner Betz, Marion Wencker, Peter Brand, Thomas Meyer, Peter Haidl.   

Abstract

The correct handling of dry powder inhalers (DPIs) is crucial for efficient therapy, and acceptance of the device can improve compliance. The handling of seven different dry powder inhalers was studied in 72 patients with asthma and chronic obstructive pulmonary disease (COPD). The aim of this study was to identify possible handling errors and investigate patient preferences. Patients inhaled twice with each inhaler; first after reading the device leaflet, and second after device handling was explained by the investigator. The investigator identified handling errors and critical handling errors, which might lead to insufficient or no dose delivery. Afterward, the patients selected their preferred device and judged different aspects of device handling. The lowest number of patients with critical handling errors was observed for the Diskus/Accuhaler, the highest numbers for the Jethaler and the Easyhaler (% of patients during first/second use): Diskus/Accuhaler 25%/13.9% (group A) and 38.9%/8.3% (group B); Clickhaler 50.0%/52.8%, Cyclohaler 58.3%/13.9%, Jethaler 66.7%/30.6% (group A) and Benosid N Inhaler 52.8%/22.2%, Novolizer 52.8%/25.0%, Easyhaler 72.2%/47.2% (group B). Device handling improved after instruction by the investigator. Device handling and preferences of patients closely correlated in this study. Both devices producing the lowest numbers of handling errors (Diskus/Accuhaler and Clickhaler) had the highest preference by the subjects (score from 1 = very good to 7 = very bad): Diskus/Accuhaler 2.21 (group A) and 2.02 (group B); Clickhaler 2.21, Cyclohaler 2.80, Jethaler 3.16 (group A); Novolizer 2.33, Easyhaler 2.37, Benosid N Inhaler 2.43 (group B). Critical handling errors may reduce therapy outcome due to a reduced dose delivery. In addition, reduced patients acceptance of a device, being dependent on device handling, may have a similar effect by reducing patients' compliance.

Entities:  

Mesh:

Year:  2008        PMID: 18823257     DOI: 10.1089/jamp.2007.0634

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  36 in total

1.  Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners.

Authors:  Mathieu Molimard; Paul Colthorpe
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-29       Impact factor: 2.849

2.  Inhalation devices and patient interface: human factors.

Authors:  Stefan Leiner; David Parkins; Orest Lastow
Journal:  AAPS J       Date:  2015-01-16       Impact factor: 4.009

Review 3.  Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).

Authors:  Sadia Janjua; Katharine C Pike; Robin Carr; Andy Coles; Rebecca Fortescue; Mitchell Batavia
Journal:  Cochrane Database Syst Rev       Date:  2021-09-08

4.  Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Authors:  Thomas Voshaar; Monica Spinola; Patrick Linnane; Alice Campanini; Daniel Lock; Anthony Lafratta; Mario Scuri; Barbara Ronca; Andrea S Melani
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

Review 5.  Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting.

Authors:  Mathieu Molimard; Ioannis Kottakis; Juergen Jauernig; Sonja Lederhilger; Ivan Nikolaev
Journal:  Clin Drug Investig       Date:  2021-03-25       Impact factor: 2.859

6.  Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease.

Authors:  Andras Koser; Jan Westerman; Sanjay Sharma; Amanda Emmett; Glenn D Crater
Journal:  Open Respir Med J       Date:  2010-10-21

7.  Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.

Authors:  Veronika Müller; Gabriella Gálffy; Noemi Eszes; György Losonczy; Andrea Bizzi; Gabriele Nicolini; Henry Chrystyn; Lilla Tamási
Journal:  BMC Pulm Med       Date:  2011-07-15       Impact factor: 3.317

8.  Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.

Authors:  Kenneth R Chapman; Charles M Fogarty; Clare Peckitt; Cheryl Lassen; Dalal Jadayel; Juergen Dederichs; Mukul Dalvi; Benjamin Kramer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-06-23

9.  Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Authors:  David Price; Monica Fletcher; Thys van der Molen
Journal:  NPJ Prim Care Respir Med       Date:  2014-06-12       Impact factor: 2.871

Review 10.  Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting.

Authors:  Barbara P Yawn; Gene L Colice; Rick Hodder
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.